The 2 biggest points for me from the results this week were:
1) 1 out of 45 patients died from the treated group vs. 3 out of 15 from the control group (very positive)
2) No dose response (very negative)
Bell Potter didn't seem to know what to make of no dose response, putting it down to the trial size being too small. I don't think that is a satisfactory answer. If you can disregard that because of the trial size then you can disregard anything including the improved survival rate.
Does anyone have thoughts on this?
Did any of the other analyst reports mention this issue?
thanks
status quo then, page-8
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.055(4.66%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.13 | $4.824M | 4.236M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25589 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |